FDA approves Bayer’s first-in-class stroke drug

The approval was granted to Bayer’s asundexian, marketed under the brand name Sunharbo. It is indicated for patients who have recently suffered a mild-to-moderate ischaemic stroke or a high-risk transient ischaemic attack (TIA), a temporary disruption of blood flow to the brain often referred to as a mini-stroke.